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Abstract
Diabetic cardiomyopathy (DCM) is an independent clinical entity defined as structural 
and functional changes in the myocardium because of metabolic and cellular abnormali-
ties induced by diabetes, resulting in cardiac failure. Hyperglycemia has been seen as 
a major cause of DCM due to activation of different mechanisms leading to oxidative 
stress. Several body of evidence show that distinct pathways of oxygen and nitrogen 
reactive species formation contribute to myocardial impairment. Abnormal mitochon-
drial morphology and energetics, evoked by abnormal Ca2+ handling, metabolic changes 
and oxidative stress, are observed in DCM, suggesting a pivotal role of mitochondrial 
dynamics in disease pathogenesis. In addition, insulin resistance compromises myocar-
dial glucose uptake due to cellular depletion of glucose transporter proteins, together 
with increased myocardial uptake of free fatty acids and augmented triglyceride levels, 
which cause cardiomyocyte lipotoxicity. Finally, the state of chronic low-grade inflam-
mation, a feature of obese type 2 diabetes, seems to also play a major role in DCM pro-
gression, whose mechanisms have been progressively disclosed. In this book chapter, we 
review the cellular mechanism contributing to DCM development, focusing on oxidative 
stress, mitochondrial dysfunction and inflammation of cardiomyocytes, as well as on 
possible therapeutic strategies.
Keywords: diabetic cardiomyopathy, oxidative stress, mitochondrial dysfunction, 
inflammation, therapeutic strategies
1. Introduction
Type 2 diabetes mellitus (T2DM) is one of the most common endocrine deregulation world-
wide, reaching pandemic proportions on a global scale [1]. In 2015, there were 415  million 
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people with diabetes globally and an increase to 642 million by 2040 is estimated by the 
International Diabetes Federation [2]. In addition, T2DM is one of the leading causes of 
illness and premature death, with 5 million deaths in 2015, mainly affecting developed 
regions (“Occidental World”), as well as many countries in development, particularly due to 
unhealthy lifestyle habits, such as physical inactivity and high fat and sugar diets [1].
T2DM is a major risk factor for the development of cardiovascular diseases (CVD), which are 
responsible for up to 65% of all deaths in diabetic patients, as well as for substantial morbidity 
and loss of quality of life. As T2DM progresses, the heart and blood vessels undergo changes, 
leading to a number of different cardiovascular complications, including coronary artery dis-
ease (CAD), stroke, peripheral arterial disease, as well as diabetic cardiomyopathy (DCM) [2].
The original finding of Rubler et al. [3] of the existence of heart failure (HF) in postmortem 
diabetic patients free of detectable CAD was the basis of the first use of DCM terminology. 
Subsequent clinical and epidemiological studies have confirmed these observations [4, 5], 
suggesting that diabetes can damage the cardiac tissue independently of other cardiovascular 
risk factors. Such associations have provided a credible existence of DCM as a unique clinical 
entity, independent of hypertension, CAD, left ventricular hypertrophy (LVH), atrial fibril-
lation, or any other known cardiac diseases, leading to HF, caused by complex relationships 
between metabolic abnormalities that accompany diabetes and its cellular consequences [6].
Despite the development of asymptomatic DCM for a long period of time, the metabolic 
anomalies at the cardiac myocyte level progresses, leading to structural and functional 
abnormalities. Although hyperglycemia has been classically indicated as the primary respon-
sible, other factors seem to be involved in the evolution of the disease and several substrates 
have been suggested [7]. During the last years, the structural, functional, pathological and 
molecular aspects of the disease have been increasingly investigated, but the issue is far to be 
elucidated and no specific markers and therapeutics have been found so far. Unravelling the 
molecular mechanisms underlying DCM development and progression is crucial to identify 
relevant therapeutic targets and generate novel therapies tailored to reduce the risk of HF in 
diabetic patients.
In this book chapter, we revisit some of the main features of DCM, focusing on pathophysi-
ological mechanisms associated with cardiomyocyte oxidative stress, mitochondrial dys-
function and inflammation. We also indicate possible therapeutic strategies targeting those 
important cellular events that seem to play a major role in DCM development and progression.
2. Structural and functional cardiac changes
Increasing evidences from experimental, pathologic, epidemiologic and clinical studies have 
been shown that diabetes results in structural and functional cardiac changes. Anatomic 
changes in DCM, mainly assessed by echocardiography or magnetic resonance imaging, are 
essentially characterized by myocardial hypertrophy and fibrosis. In addition, although many 
studies have shown that diabetic patients have abnormal diastolic function but preserved sys-
tolic function, which might be due to the lower sensitivity to detect systolic dysfunction by 
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some of the techniques used, the current knowledge points to the existence of a continuum of 
diastolic and systolic dysfunction in DCM.
2.1. Cardiac hypertrophy
One of the most important structural hallmarks of DCM is cardiac hypertrophy, which is a 
powerful predictor of cardiovascular events. Apoptotic and necrotic loss of cardiomyocytes 
causes compensatory hypertrophy of the remaining viable cardiomyocyte. Although the right 
ventricle can also become hypertrophic, LVH is more common and generally represents a 
more advanced stage of the disease. Even though the causes and mechanisms underlying 
LVH development in diabetic patients remain poorly understood, experimental and clinical 
studies have been suggesting that hyperinsulinemia, insulin resistance, hyperglycemia, and 
increased nonesterified fatty acids (NEFAs) may collectively play a major role. Insulin, in par-
ticular, is viewed as a growth factor in the myocardium, which is sustained by experimental 
findings that sustained hyperinsulinemia causes increased myocardial mass and decreased 
cardiac output in rats [8]. In addition, clinical and experimental data have been shown 
increased markers of cardiomyocyte hypertrophy, including augmented width and myofiber 
disarray of cardiomyocyte, as well overexpression of hypertrophic genes, namely β-myosin 
heavy chain, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) [9, 10].
2.2. Myocardial fibrosis, apoptosis and necrosis
Myocardial fibrosis has been indicated as another major mechanism contributing to cardiac 
alterations in DCM. This pathological feature of DCM that have been observed in diabetic 
patients without significant CAD and in animal models, results from the accumulation of 
interstitial glycoproteins and increased extracellular collagen matrix, which potentiates stiffen-
ing and inhibits ventricles relaxation [11, 12]. The echocardiographic features of increased left 
ventricular fibrosis appear in the form of impaired relaxation and diastolic dysfunction; con-
sequently, alterations in collagen phenotype may play an important role in the impaired left 
ventricular diastolic filling that is typical of DCM [11]. It has been suggested that collagen is a 
major determinant of ventricular stiffness. In a study with rats, a correlation between increased 
extracellular collagen content and decrease in early mitral peak flow (decreased E/A ratio) 
was reported [12]. The cause for the accumulation of cardiac fibrosis in diabetes is believed to 
result from decreased degradation of glycosylated collagen by matrix metalloproteinases and, 
conversely, from excessive production of collagen by fibroblasts due to increased renin–angio-
tensin–aldosterone system (RAAS) activation [11]. Furthermore, increased formation in myo-
cardial advanced glycation end-products (AGEs) has also been reported in diabetic patients, 
which has been attributed to hyperglycemia [13]. In fact, collagen cross-linked with AGEs 
causes myocardial stiffness and inhibits collagen degradation, which promotes additional col-
lagen accumulation and fibrosis [11, 13]. This mechanism seems to be also a major contributor 
for the impaired left ventricular diastolic function observed in diabetic patients [13].
Finally, DCM is associated with increased myocyte cell death and apoptosis. Accelerated necro-
sis and apoptosis is caused by hyperglycemia, increased formation of ROS,  overactivation of 
local RAAS system and of insulin-like growth factor-1 and transforming growth factor beta 1 
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(TGF-β1) [14]. While apoptosis does not cause scar formation or accumulation of interstitial 
collagen, because nuclear fragmentation and cell shrinkage is replaced by the surrounding 
cells, necrosis is able to promote the widening of extracellular compartments among myo-
cytes and increased deposition of collagen, which causes replacement fibrosis and connective 
cell proliferation [15].
2.3. Diastolic dysfunction
In many cases, it has been found that abnormalities of diastolic function may advertise the 
subsequent progressive deterioration of cardiac function. Diastolic dysfunction is the basic 
hemodynamic feature and the earliest findings of DCM that can be detected using imaging 
techniques. The noninvasive assessment of diastolic dysfunction mainly relies on Doppler 
studies of diastolic transmitral inflow, flow velocities, flow patterns, isovolumic relaxation 
time and deceleration time, which are the most common criteria used in its evaluation. The 
criteria of the consensus statement on the diagnosis of heart failure with normal left ventricu-
lar ejection fraction by the Heart Failure and Echocardiography Associations of the European 
Society of Cardiology have been used to assess left ventricular diastolic dysfunction [16].
Diastolic dysfunction is characterized by an abnormal myocardial relaxation and filling. This 
condition is typically manifested by reduced early diastolic filling and increased atrial filling, 
by augmented isovolumetric relaxation and increased number of supraventricular premature 
beats, as well as by amplified left ventricular end-diastolic pressure and diminished left ven-
tricular end-diastolic volume [17–19].
Diastolic dysfunction is found in several other cardiovascular diseases, such as hyperten-
sion, hypertrophic cardiomyopathy and CAD, even with intact systolic function. However, 
experimental and clinical studies have shown impaired diastolic function in the absence of 
manifestations of congestive HF, even in prediabetes or in early stages of diabetes [19], thus 
suggesting that could be a useful early marker for disease prognosis. Furthermore, left ven-
tricular diastolic dysfunction may progress to a systolic dysfunction, causing reduced left 
ventricular ejection fraction (LVEF) in years. Therefore, it is very important to detect left ven-
tricular diastolic dysfunction in diabetic patients, both for early diagnosis and treatment of 
DCM, as well as for prevention of further systolic dysfunction.
2.4. Systolic dysfunction
Systolic dysfunction, defined as impaired ability of the heart to pump arterial blood in the 
periphery, is typically associated with a reduced LVEF and cardiac output. In DCM, sys-
tolic dysfunction occurs late, often when patients have already developed significant diastolic 
dysfunction. The presence of systolic dysfunction in the early years of diabetes has been a 
controversial issue, while diastolic dysfunction is more easily detected by Doppler echocar-
diography. The controversy relies on the fact that current techniques used to assess systolic 
function are less sensitive than those used for diastolic dysfunction evaluation. For this rea-
son, more sensitive and accurately techniques for systolic assessment have been developed, 
such as tissue Doppler imaging (TDI) and strain rate imaging techniques, which are able 
to estimate left ventricular function in longitudinal, radial and circumferential ways, thus 
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allowing the detection of preclinical systolic abnormalities in diabetic patients. Currently, 
shortened left ventricular ejection time, decreased peak systolic velocity (S′), and smaller left 
ventricular fractional shortening can be the detectable parameters for identification of systolic 
dysfunction [20]. The prognosis in patients with depressed systolic dysfunction is poor with 
an annual mortality of 15–20%.
3. Overview of the molecular mechanisms involved in DCM development
The pathophysiological molecular mechanisms underlying the development and progression 
of DCM are multifactorial and complex and have been progressively disclosed. Some of the 
main features of DM are also pivotal elements in the pathogenesis of DCM, including hyper-
glycemia, hyperinsulinemia and insulin resistance, as well as hyperlipidemia (Figure 1).
Hyperglycemia has been seen as a major cause of DCM development due to activation of the 
classical oxidative stress pathways (polyol, hexosamine, AGEs and protein kinase C—PKC). 
These mechanisms cause increased production of mitochondrial reactive oxygen species 
(ROS), nonenzymatic glycation of proteins and glucose auto-oxidation, thus leading to cel-
lular (cardiac) injury—glucotoxicity. Glucose and collagen interact to form Schiff bases and 
the fibrous network is reorganized with the so-called Amadori products, which can be trans-
formed in AGEs. As above mentioned, the increased formation of AGEs is highly  associated 
Figure 1. Metabolic abnormalities underlying T2DM that are considered the main triggers for the cellular and molecular 
pathways associated with structural and functional changes in DCM. Adapted with permission from Ref. [24]. 
Abbreviations: AGEs, advanced glycation end products; FFAs, free fatty acids, NF-κB, nuclear factor-κB; RAAS, renin–
angiotensin–aldosterone system; ROS, reactive oxygen species; TLRs, Toll-like receptors.
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with myocardial fibrosis in diabetic hearts by affecting the structural components of the 
extracellular matrix, such as collagen. This stable cross-linked collagen accumulate in vessel 
walls and in myocardial tissue, increasing diastolic stiffness of the heart and contributing to 
endothelial dysfunction, thus suggesting a key role of AGEs in DCM development.
Insulin resistance originates cellular depletion of glucose transporter proteins (GLUT-1 and 
GLUT-4) leading to reduced glucose uptake in the diabetic heart, which facilitates a substrate 
shift towards increased fatty acids (FAs) oxidation, resulting in reduced cardiac efficiency 
[21]. In brief, once inside the cardiomyocytes, the free fatty acids (FFAs) are converted into 
acetyl coenzyme A derivatives that will activate PKC isoforms responsible for blocking insu-
lin cascade elevated levels of FFAs compete with glucose as energy substrate, with a shift in 
energy production from β-oxidation of FFAs. As a result, there is a reduced glucose utilization 
and oxidation, increased glucose and insulin levels, promoting insulin resistance.
Additionally, the increase concentration of FFAs and of its metabolism causes intracellular 
accumulation of toxic FA intermediates (such as ceramide and diacylglycerol) and forma-
tion of ROS. These mechanisms originates cardiac lipotoxicity by means of oxidative stress, 
cardiomyocyte apoptosis and increased myocardial consumption of oxygen, resulting in 
impaired contractility, mitochondrial uncoupling and decreased adenosine triphosphate 
(ATP) availability [22]. Intracellular deposition of FFAs is also responsible for the saturation 
of the mitochondrial capacity of oxidation, thus activating transcription factors, including the 
peroxisome proliferator-activated receptors (PPARs), which has been indicated as an induc-
tor of cardiac lipotoxicity and dysfunction [23]. Several body of evidences show that distinct 
pathways of oxygen and nitrogen reactive species formation contribute to myocardial injury. 
Impaired mitochondrial morphology and energetics, evoked by abnormal Ca2+ handling, 
metabolic changes and oxidative stress, are observed in DCM, suggesting a pivotal role of 
mitochondrial dynamics in disease pathogenesis.
In addition, the state of chronic low-grade inflammation, a feature of obese T2DM, seems 
to also play a major role in DCM progression, whose mechanisms have been progressively 
disclosed [24]. The epicardial adipose tissue (EAT) that covers 80% of the heart surface and 
constitutes approximately 20% of the total heart weight have endocrine and paracrine proper-
ties that interfere with cardiac function, namely by the development of inflammation, insulin 
resistance and cardiac dysfunction [25].
As above mentioned, activation of the RAAS, locally and systemically, has been associated 
with the development of insulin resistance and the onset of T2DM. In addition, it has been 
associated with some of the hallmarks of DCM, such as increased fibrosis, oxidative damage, 
and cardiomyocyte and endothelial cell apoptosis and necrosis [26].
4. Oxidative stress and mitochondrial dysfunction
Mitochondria are dynamic organelles with a key role in energy transduction, signaling 
and cell death pathways. Consequently, mitochondrial dysfunction and oxidative stress 
are broadly relevant in the development of cardiovascular diseases, in both acquired and 
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 inherited disease [27]. Tissues with high aerobic metabolism demands, such as the heart mus-
cle, are severely affected by a decline in mitochondrial efficiency such as in the context of 
diabetes, ischemia-reperfusion and aging [28, 29], associated with loss of calcium homeostasis 
and impaired contractile function. In fact, mitochondria comprise one-third of the volume of 
the heart and support the vast majority of ATP production derived from oxidation of fatty 
acids (FAs) and glucose, being FAs the preferred substrate in the normal adult myocardium, 
while failing human hearts shift to oxidizing glucose for energy production.
In the inner mitochondrial membrane, electrons deriving from the oxidation of NADH and 
FADH2 are funneled through the electron transport chain. This flow is coupled with the trans-
location of protons across the inner mitochondrial membrane to the intermembrane space, 
generating an electrochemical gradient. Under normal conditions, much of the energy of this 
gradient is used to generate ATP, as the collapse of the proton gradient through ATP synthase 
drives the ATP synthetic machinery. However, when the electrochemical potential difference 
generated by the electrochemical gradient is high (such as in high-fat or high-glucose states), 
or under conditions of inhibition of the ETC complexes, the life of superoxide-generating 
electron transport intermediates, such as ubisemiquinone radical, is prolonged [30], resulting 
in increased ROS generation. Although ROS are produced in multiple cell compartments, the 
majority of cellular ROS (approximately 90%) are mitochondrial, mainly at the level of com-
plexes I and III of the ETC [31]. The activity of detoxifying enzymes and uncoupling proteins 
limits ROS generation. In the healthy myocardium, ROS concentration is tightly controlled to 
low steady-state level by superoxide dismutase (SOD) [32]. Superoxide anion is dismutated 
by mitochondrial manganese SOD into hydrogen peroxide, which is detoxified into water 
by the mitochondrial glutathione peroxidase (GPx), an action dependent on mitochondrial 
reduced glutathione (GSH) content. Mitochondrial catalase has a detoxifying effect against 
overproduction of hydrogen peroxide. An imbalance of antioxidant defenses that favors the 
accumulation of oxidants, expose mitochondria to oxidative stress, with ROS reacting with 
DNA, proteins and lipids, inactivating the ETC complexes and mitochondrial proteins, thus 
impairing both oxidative phosphorylation (OXPHOS) and inducing ROS accumulation. In 
the diabetic heart, increased FAs accumulation and metabolism is linked to oxidative stress 
[33]. Also, in the context of myocardial ischemia/reperfusion, oxidative stress is implicated 
in ATP depletion and cardiomyocyte death. At the onset of reperfusion, increased ROS and 
mitochondrial calcium influx favor induction of the mitochondrial permeability transition 
(MPT) and loss of mitochondrial inner membrane impermeability [34]. Recently, it has been 
shown that offspring of diabetic pregnancies are at risk of cardiovascular disease at birth 
and throughout life, with high-fat diet-exposed offspring exhibiting mitochondrial dysfunc-
tion and lipid peroxidation [35]. Each cell has normally several copies of mitochondrial DNA 
(mtDNA) which encodes ribosomal and transfer RNAs necessary for the synthesis of the 
mtDNA-encoded 13 OXPHOS polypeptides in the mitochondrial matrix [36]. The proximity 
to the inner membrane, the absence of protective histones, and incomplete repair mecha-
nisms in mitochondria, renders mtDNA extremely sensitive to oxidative damage. The accu-
mulation of mtDNA mutations due to oxidative damage results in further unbalanced ETC 
and increased ROS generation, perpetuating oxidative damage and enhancing inflammatory, 
hypertrophic, fibrotic, and cell death events in the myocardium [37]. Therefore, mechanisms 
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able to eliminate dysfunctional mitochondria are essential to prevent the cytotoxic impact of 
ROS and thus maintain cellular homeostasis.
Autophagy is a tightly regulated cellular process which promotes the turnover of dysfunc-
tional mitochondria along with the elimination of long-lived proteins and other damaged 
organelles, being essential for maintaining normal cardiac function [38]. Autophagy also main-
tains cell viability under stress conditions by supplying amino acids for de novo protein syn-
thesis and providing substrates for the tricarboxylic acid cycle [39], as shown by myocardial 
survival promoted by activation of autophagy upon starvation or ischemia [40, 41]. Autophagy 
is redox-dependent due to redox regulation of metabolic alterations as well as ROS-mediated 
modification of autophagy-regulatory proteins. Disruption of ATG5, an autophagy-related 
gene, results in heart failure under basal and stress conditions [42]. In turn, autophagy regulates 
intracellular ROS by selective elimination of dysfunctional mitochondria (mitophagy) [43] and 
degradation of KEAP1 and activation of the nuclear factor erythroid 2-related factor 2 (NRF2), 
activating the expression of antioxidant genes such as glutathione peroxidase, superoxide dis-
mutase and thioredoxin [44]. A decline in autophagy with aging, leading to increased levels of 
oxidative damage and the accumulation of dysfunctional mitochondria has been proposed as 
an underlying cause for the pathogenesis of cardiovascular diseases prevalent in late life [45].
Besides mitophagy, mitochondrial quality control is dependent on balanced fusion and fis-
sion events that continually alter mitochondrial morphology by undergoing fission to gener-
ate discrete fragmented mitochondria or fusion to form an interconnected elongated network. 
This dynamic behavior shapes mitochondria to adapt metabolism to the energetic needs of 
the cell, allows mixing of mtDNA, lipids, proteins and metabolites, enhances communica-
tion with the endoplasmic reticulum or segregates dysfunctional or depolarized mitochon-
dria away from the healthy network, facilitating its clearance [46]. These two processes are 
under the control of mitochondrial fission and fusion proteins: mitofusins (MFN1 and MFN2) 
and optic atrophy 1 (OPA1) mediate mitochondrial fusion while dynamin-related protein 1 
(DRP1) mediates mitochondrial fission by interaction with other fission mediators such as 
 fission protein (FIS1) [47]. Changes on mitochondrial morphology, linked to altered expres-
sion of DRP1 and MFN2, are evident during stem cell differentiation into cardiomyocytes, 
transitioning from fragmented rounded mitochondria into an elongated network with well-
developed cristae and an efficient OXPHOS system [48]. The essential role of MFN proteins 
is also shown by mitochondrial fragmentation, impaired mitochondrial function and devel-
opment of heart failure in models of conditional cardiac ablation of MFN 1 and 2 [49]. In 
post-mitotic tissues with high metabolic demands, such as the heart, abnormal mitochondrial 
dynamics results in the development of cardiovascular disease, due to impaired mitochon-
drial turnover and accumulation of fragmented and depolarized mitochondria, sources of 
increased ROS generation [50]. Recently, it has also been shown that DRP1 ablation results 
in cardiomyocyte necrosis and dilated cardiomyopathy in mice, mitophagic mitochondrial 
depletion and favors MPT induction, probably linked to spatiotemporal alterations in calcium 
signaling [51]. When exposed to calcium overload, both neonatal and adult rat cardiomyo-
cytes exhibited increased ROS generation and mitochondrial fragmentation, which suggested 
that activation of the fission machinery may be an event preceding ROS generation regulated 
by calcium  signaling [52]. Giant or mega-mitochondria have been described in a variety of 
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cardiomyopathies, including those associated with mtDNA mutations [53]. The observa-
tion of increased mtDNA content, induction of genes involved in mitochondrial biogenesis, 
fatty acid metabolism, and glucose transport, as well as uncoupling proteins and antioxidant 
enzymes in mitochondrial cardiomyopathies hearts, may indicate a compensatory response, 
although unable to prevent energy depletion and increased ROS generation [54].
Balanced fusion–fission events are essential for normal mitochondrial biogenesis, the process 
by which cells increase mitochondrial mass and copy number. Among the transcription factors 
involved in this process, peroxisome proliferator-activated receptor-γ coactivator-1, PGC-1α, 
is the master regulator. This inducible coactivator acts as a coactivator of the transcription 
factors involved in the expression of nuclear/mitochondrial genes and bioenergetic capacity, 
as well as regulates cardiac fuel selection and mitochondrial ATP-producing capacity [55]. 
An interplay between PGC-1α and MFN-2 has been shown as follows: MFN2 is critical for 
the stimulatory effect of PGC-1α on mitochondrial membrane potential while PGC-1α may 
regulate mitochondrial fusion/fission events [56]. Besides stimulating mitochondrial biogen-
esis and OXPHOS, PGC-1α prevents oxidative stress by inducing ROS-detoxifying enzymes 
[57]. Sirtuin 3 (SIRT3) has been shown essential for the stimulatory effect of PGC-1α on both 
mitochondrial biogenesis and ROS-detoxifying enzymes [58]. Sirtuins (1–7) are a conserved 
family of NAD+-dependent lysine-modifying acylases that regulate a variety of cellular func-
tions such as metabolic responses to diet and exercise [59]. The decline in NAD+ during aging 
decreases sirtuin activity thus impairing the transcription of mitochondrial OXPHOS genes 
which leads to cardiovascular disease, an event precipitated by SIRT1 deletion [60]. Cardiac 
SIRT1 is upregulated during nutrient starvation, exercise and ischemic preconditioning while 
downregulated during I/R [61]. SIRT3, which exhibits mitochondrial deacetylase activity, 
deacetylates and increases the activity of mitochondrial metabolic and antioxidant enzymes 
[62] as well as regulates mitochondrial fusion–fission dynamics [63]. By deacetylating and 
suppressing the activity of cyclophilin D, SIRT3 increases resistance to MPT induction, pre-
venting cell death and cardiac hypertrophy [64].
5. Inflammation
Chronic low-grade inflammation is commonly associated with obesity and T2DM, and clear 
evidence has emerged to suggest that inflammatory process also contributes to the pathogen-
esis of DCM. The inflammatory signaling in cardiomyocytes usually occurs as an early response 
to myocardial injury and involves an increased formation of cytosolic and mainly mitochon-
drial ROS. Several molecular pathways have been classically associated with the inflammatory 
response in the cardiac tissue: increased activation of the proinflammatory nuclear transcription 
factor-κB (NF-κB), overexpression of cytokines [namely the tumor necrosis factor-α (TNFα), 
some interleukins (such as IL-1β and IL-6), chemokines (i.e., monocyte chemotactic protein-1: 
MCP-1), adhesion molecules (i.e., selectins and adhesion molecules (ICAM-1, VCAM-1)] and 
migration of leukocytes into the myocardium [24]. There is evidence that chronic progression of 
hypertrophy, fibrosis and ventricular dysfunction is  correlated with a local increase in cytokines 
and activation of NF-κB [65]. Activation of NF-κB is associated with the increased release of 
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 cytokines, such as TNF-α and IL-6, which are often involved in cardiac damage (hypertrophy and 
 fibrosis) and left ventricular dysfunction [65, 66]. Accumulating data have been demonstrated 
that increased IL-1β and TNF-α are implicated in DCM, increasing epicardial thickness, promot-
ing myocyte contractile dysfunction, thus depressing myocardial function and contributing to 
HF [67]. The inflammatory stimuli in the diabetic heart include hyperglycemia, hyperlipidemia, 
ROS, angiotensin II and the activation of Toll-like receptors (TLRs). Hyperglycemia-induced 
oxidative stress and inflammation seem to be deeply correlated with development of DCM. 
In fact, hyperglycemia activates several oxidative stress-responsive/proinflammatory transcrip-
tion factors, including NF-κB, which is able to induce collagen and fibronectin synthesis, as 
well as to stimulate the production of inflammatory cytokines. Hyperglycemia-evoked diastolic 
dysfunction may be mediated partly by the macrophage migration inhibitory factor, suggesting 
that the NF-κB pathways may be involved in this process [68].
RAAS overactivation seems to also play an important role in the modulation of inflamma-
tion associated with DCM. In fact, Ang II not only induces vasoconstriction, cell growth and 
oxidative stress but also stimulates inflammation, namely by inducting cytokines release, 
by stimulating the production of PAI-1 and pro-inflammatory transcription factors, such as 
NF-κB, which in turn regulate adhesion molecules (VCAM-1 and ICAM-1) and the expression 
of several cytokines [69].
Activation of TLRs and the inflammasome complex has been recently proposed to play a piv-
otal role in cardiac inflammation and likely in the pathogenesis of DCM [70]. Accumulating 
evidences support the hypothesis that hyperglycemia and FFA are able to stimulate TLRs, 
thus inducing proinflammatory pathways in DCM. In fact, TLR-dependent NF-κB and ROS 
seem to be able to regulate both the priming and the posttranslational pathways required for 
the assembly and activation of the inflammasome, thus opening new therapeutic opportuni-
ties to DCM treatment, as further discussed.
6. Therapeutic strategies
Despite a specific therapy for the treatment or prevention of DCM is still lacking, some thera-
peutic strategies could present potential benefits. The advances on the knowledge of DCM 
pathogenesis provides us with improved management options, including lifestyle measures, 
strategies to improve diabetic control, lipid lowering therapy, as well as agents directed to 
target some of the main molecular events and mechanisms underlying DCM development 
and progression, including fibrosis, hypertrophy, oxidative stress and inflammation.
6.1. Physical exercise
Regular physical activity (training) has been associated with improved glycemic control 
and insulin sensitivity, as well as with amelioration of the metabolism of glucose and fatty 
acids in heart muscle, thus improving left ventricular function and attenuating diabetes 
induced-cardiac alterations. Physical exercise has also greater anti-inflammatory effects by 
decreasing the release of inflammatory cytokines from the skeletal muscles endothelial cells 
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and immune system, together with increasing the anti-inflammatory cytokines, such as adi-
ponectin [71]. In an animal model of T2DM, the Zucker Diabetic Fatty (ZDF) rat regular 
aerobic exercise (training) was able to not only improve the glycemic control and attenuate 
dyslipidaemia, but also to promote an anti-inflammatory effect, viewed by the reduction in 
pro-inflammatory cytokines, such as TNF-α and CRP, and by the increment of adiponectin 
levels [72–74]. This effect occurred independently of weight loss and was not observed when 
an acute extenuating exercise was used [75].
6.2. Antidiabetic agents
Improvement of glycemic control has been shown to be associated with better outcomes 
in diabetic microvascular complications in many clinical trials. Even though the impact of 
strict glycemic control on macrovascular outcomes remains debatable, the recognized role of 
microvascular disease in DCM development suggests that a better glycemic control would 
benefit patients.
6.2.1. Insulin-sensitizing agents
Insulin resistance is a hallmark of T2DM and plays an important role in the pathogenesis 
of DCM. Accordingly, agents used to ameliorate insulin resistance might be useful to pre-
vent DCM progression. The beneficial effects of insulin may rely not only on the improved 
glycemic control in some patients but also on cardioprotective anti-inflammatory properties. 
Several data show a reduction in adhesion molecules, such as ICAM-1 and E-selection, circu-
lating CRP, IL-6 and PAI-1 due to insulin-sensitizing therapy [76]. Metformin, one of the most 
commonly prescribed anti-diabetic drugs and a known insulin-sensitizing agent, improves 
peripheral sensitivity to insulin and promotes intensive glucose control [77]. Besides, cardio-
protective actions of metformin have been described, namely inhibition of hypertrophy and 
pro-authophagic and anti-inflammatory actions [78].
The possible beneficial effects of thiazolidinediones (TZDs) and PPAR agonists on the myocar-
dium have been demonstrated in several studies. Pioglitazone was associated with improved 
diabetic cardiac function in animal models, by raising myocardial glucose uptake and improv-
ing myocardial fatty acid metabolism [79]. In addition, rosiglitazone showed an ameliora-
tion of myocardial diastolic function in T2DM patients, which was related to an antioxidant 
and anti-inflammatory effect [80]. Other factors involved in improved cardiac function with 
TZDs therapy include decreased collagen accumulation and fibrosis, as well as inhibition of 
cardiomyocyte hypertrophy [79, 81]. Pioglitazone and rosiglitazone stimulate the PPAR-γ, 
which regulates important genes for the metabolism of glucose and fat and enhance insulin 
sensitivity in skeletal muscle and adipose tissue [82]. Additionally, PPAR activators may have 
anti-inflammatory effects by inhibition of TNF-α expression at the transcriptional level due to 
attenuation of NF-κB activity in cardiomyocytes [83]. However, the effects of this therapy on 
cardiac function in patients with T2DM have not yet been fully elucidated. On the other hand, 
experimental studies using PPARα agonists suggested cardiac benefits related to apoptosis 
and hypertrophy [84]. However, further research is still required in order to fully understand 
the role of PPARα agonists, as well as TZDs, in DCM.




Glucagon-like peptide-1 (GLP-1), an incretin hormone rapidly released by the L-cells of the 
small intestine after a meal intake, presents several actions that contribute to glucose homeo-
stasis, including stimulation of postprandial insulin secretion by pancreatic beta cells, thus 
improving insulin sensitivity. GLP-1 is metabolized by the enzyme dipeptidyl peptidase 4 
(DPP-4), thus inactivating their insulinotropic activities. In diabetic patients, the incretin 
effect is partially blunted, which contributes to a poor glycemic control. The incretin-based 
therapies, a new class of antidiabetic drugs currently available for the treatment of diabetic 
patients, include DPP-4 inhibitors (such as sitagliptin) and GLP-1 receptor (GLP-1R) ago-
nists (namely exenatide). GLP-1R and DPP-4 are expressed in several extra-pancreatic tissues, 
including the heart, which has encouraged studies concerning its role in cardiac physiology, 
as well putative cardiac and cardiovascular benefits of incretin-based therapies.
Several body of experimental and clinical data have suggested a considerable cardioprotec-
tive role of GLP-1 agonists in the myocardium. Myocardial ischemia-reperfusion injury was 
attenuated by GLP-1 in vitro rat hearts, showing cardioprotective and inotropic effects [85]. 
Furthermore, it has been shown that mice with genetic deletion of GLP-1 receptor display 
reduced heart rate, elevated left ventricular end-diastolic pressure and impaired left ventricu-
lar contractility and diastolic function after insulin administration. Furthermore, infusion of 
GLP-1 resulted in improved left ventricular function, hemodynamic status and efficiency, 
indicating a direct role of GLP-1 on the cardiac physiology [86]. Apart the clinical pharmaco-
logical effects on body weight reduction, amelioration of blood pressure and improvement of 
glycemic control and lipid profile, GLP-1R agonists have been experimentally shown to exert 
antioxidant, vasoprotective and anti-inflammatory properties. One of these studies showed 
that liraglutide exerts anti-inflammatory effect on vascular endothelial cells through increased 
NO production and suppressed NF-κB activation, which is at least partly mediated via AMPK 
activation [87]. In another study, liraglutide was able to ameliorate cardiac hypertrophy in 
mice [88]. However, further research is advisory to better understand the complete benefits of 
GLP-1R agonists in the treatment of DCM.
DPP-4 inhibitors are able to increase the endogenous contents of incretins, such as GLP-1. 
Besides their effect on glycemic control, beneficial actions on other tissues, including on the 
heart tissue, have been shown, which might be due to anti-inflammatory, antioxidant and 
anti-apoptotic properties [89–94]. DPP-IV inhibitors have the advantage of being available for 
oral administration and do not raise supra-physiological concentration of GLP-1. However, 
further research is needed to elucidate the effective relevance of DPP-IV inhibitors in DCM.
6.3. Other non-antidiabetic agents
6.3.1. Statins
Statins are primarily inhibitors of cholesterol biosynthesis and the control of hyperlipid-
emia will benefit T2DM patients. However, although the key benefits of statins were initially 
attributed to their lipid lowering effects, it is now known that they directly act through other 
cellular mechanisms, known as pleiotropic effects [95]. Statins increase the expression and 
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activation of eNOS thus causing an increase in the bioavailability of nitric oxide (NO), which 
contribute to the reduction in blood thrombogenicity, of oxidative stress and of cell prolif-
eration. In addition, statins may also exert anti-inflammatory effects by several pathways, 
including reduced activity of VCAM-1 and ICAM-1, decreased function and levels of MCP-1 
and decreased CRP [96]. Atorvastatin have been associated with improved left ventricular 
function, reduced fibrosis and hypertrophy; the protective effects on cardiac remodeling have 
been attributed to its anti-inflammatory actions [97]. However, further studies should be con-
ducted to better evaluate the possible beneficial effects in DCM.
6.3.2. RAAS inhibitors
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) 
are the most used drugs to block the RAAS, and there are numerous evidences suggesting 
that these antihypertensive agents reduce cardiovascular mortality in diabetic patients due to 
improvement of cardiac dysfunction [98]. ACEI and ARBs have been associated with several 
beneficial properties at cardiac level, including improved cardiac fibrosis, reduced collagen 
synthesis and deposition, amelioration of cardiomyocyte apoptosis and cardiac hypertrophy 
[98–100]. Experimental and clinical studies also suggest a beneficial effect on T2DM by ame-
liorating insulin sensitivity, enhancing glucose uptake, improving pancreatic and skeletal 
muscle blood flow and stimulating proliferation and differentiation of adipocytes, beyond 
the reduction in blood pressure [99]. Additionally, inhibition of Ang II production and/or 
action with ACEI and ARBs attenuate its pro-inflammatory actions. In fact, although further 
clinical evidences are still needed, several studies have showed beneficial effect on markers of 
inflammation (such as TNF-α, IL-6 and IFN-γ) in heart failure patients [100].
6.3.3. Modulators of mitochondrial function
Numerous studies have highlighted the pivotal importance of impaired mitochondrial metab-
olism and increased formation of ROS in the pathogenesis of cardiac dysfunction, as discussed 
previously. Therefore, strategies aiming at modulation of different aspects of mitochondria 
such as biogenesis, fusion and fission, mitophagy, MPT and ROS generation may lead to effec-
tive treatments for cardiomyopathies [101]. Modulation of sirtuins activity,  exercise-induced 
PGC-1 activation, fission and fusion as well as autophagy/mitophagy [102–105] are  examples. 
Interestingly, although increased ROS generation and consequent oxidative damage is asso-
ciated with pathological processes, mild levels of mitochondrial-derived ROS have been 
proposed to induce a hormetic response. The concept of mitohormesis proposes that a mild 
increase in mitochondrial ROS may act as a sublethal trigger of cytoprotective long-lasting 
metabolic and biochemical changes against larger subsequent stresses [106]. This approach 
was addressed in mice as a pathway to stimulate mitochondrial energy metabolism and to 
induce antioxidant defenses, thus preventing cardiomyopathy induced by the cardiotoxic 
doxorubicin [107], an effect that was also triggered by exercise [108]. Moreover, it has been 
shown that the development of cardiomyopathy due to impaired mitophagy and consequent 
accumulation of damaged ROS-forming mitochondria can be surprisingly improved by 
 ROS-dependent activation of compensatory autophagic pathways of mitochondrial quality 
control, preventing a vicious cycle of ROS formation and mitochondrial dysfunction [109].




Over the years, DCM has evolved from a nebulous concept to concrete reality and is now viewed 
as a specific clinical entity caused by the complex relationships between metabolic abnormali-
ties that accompany diabetes, resulting in functional and structural changes in the myocardium 
that ultimately leads to HF. DCM involves the damage of the myocardium through several 
mechanisms, namely hypertrophy, fibrosis, apoptosis and necrosis of cardiomyocytes. Some 
of the main factors involved in diabetes pathogenesis are also pivotal in DCM development, 
including hyperglycemia-evoked oxidative stress and mitochondrial dysfunction (by impaired 
autophagy, mitophagy and fusion–fission balance), hyperlipidemia, accompanied by inflam-
mation and a switch of substrate supply to FFAs, as well as insulin resistance. Increasing body 
of evidence suggests the existence of relevant links between some of these pathways, includ-
ing between oxidative energy metabolism dysregulation, impaired mitochondrial morphology 
and energetics evoked by abnormal Ca2+ handling, metabolic changes and oxidative stress, as 
well as chronic low-grade inflammation. The improved knowledge regarding the molecular 
mechanisms underlying DCM development has contributed to identify novel putative targets 
and therapeutic opportunities for the management of DCM. Pharmacological options target-
ing hyperglycemia, insulin resistance and reduced sensitivity, hyperlipidemia, inflammation, 
oxidative stress and mitochondrial dysfunction have been increasingly investigated, and it is 
hoped that could significantly improve the ability to prevent and/or improve management of 
DCM.
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